Latest News & Features
Americas
Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss. 15 October 2024
Europe
Global law firm recruits former CMS partner to IP practice I Patent lawyer brings expertise in pharmaceuticals, tech and AI 15 October 2024
Careers
US firm doubles down in Europe with another big name recruit | Tech and life sciences litigation at the UPC a target | Powell will 'always be a friend of the firm’ says ex-colleague Penny Gilbert | Move ends speculation about Powell’s future after August resignation. 14 October 2024
Europe
Value-for-money UPC is worth it says GSK corporate counsel | Court offers alternative to costly US litigation | Head of vaccine patents says UPC offers “strategic plank” in Europe. 10 October 2024
Europe
Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US. 10 October 2024
Europe
Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen. 9 October 2024
Europe
A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing. 8 October 2024
Americas
Judge says use of patented protein mNeonGreen not covered by Section 271(e)(1) provision I Allele granted summary judgment in patent infringement suit. 8 October 2024
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP. 8 October 2024
Americas
Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future. 3 October 2024